Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Total Non-Current Liabilities (2016 - 2025)

Adma Biologics (ADMA) has disclosed Total Non-Current Liabilities for 14 consecutive years, with $146.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 5.47% year-over-year to $146.9 million, compared with a TTM value of $146.9 million through Dec 2025, up 5.47%, and an annual FY2025 reading of $146.9 million, up 5.47% over the prior year.
  • Total Non-Current Liabilities was $146.9 million for Q4 2025 at Adma Biologics, up from $137.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $199.8 million in Q3 2022 and bottomed at $120.4 million in Q2 2021.
  • Average Total Non-Current Liabilities over 5 years is $165.9 million, with a median of $170.4 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 51.26% in 2022, then plummeted 30.3% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $134.7 million in 2021, then skyrocketed by 45.63% to $196.1 million in 2022, then dropped by 1.32% to $193.6 million in 2023, then decreased by 28.03% to $139.3 million in 2024, then increased by 5.47% to $146.9 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ADMA at $146.9 million in Q4 2025, $137.4 million in Q3 2025, and $160.1 million in Q2 2025.